bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2019-4-1-12-20bekhterev-292Research ArticleНАУЧНО-ИССЛЕДОВАТЕЛЬСКИЕ РАБОТЫRESEARCH PAPERSФармакогенетика химических зависимостейPharmacogenetics of chemical addictionsКрупицкийЕ. М.KrupitskyE. M.kruenator@gmail.comАхметоваЭ. А.AkhmetovaE. A.aea1202@yandex.ruАсадуллинА. Р.AsadullinA. R.droar@yandex.ruФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» МЗ РФ; Российский национальный консорциум по психиатрической генетикеРоссияV.M. Bekhterev national research medical center for psychiatry and neurologyRussian FederationФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» МЗ РФ; ФГБУ ВО «Башкирский государственный медицинский университет» МЗ РФРоссияV.M. Bekhterev national research medical center for psychiatry and neurology; Bashkir State Medical UniversityRussian FederationФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» МЗ РФ; ФГБУ ВО «Башкирский государственный медицинский университет» МЗ РФРоссияV.M. Bekhterev national research medical center for psychiatry and neurology; Bashkir State Medical UniversityRussian Federation20190612201904-11220Copyright © Крупицкий Е.М., Ахметова Э.А., Асадуллин А.Р., 20192019Крупицкий Е.М., Ахметова Э.А., Асадуллин А.Р.Krupitsky E.M., Akhmetova E.A., Asadullin A.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/292

В обзоре рассматриваются результаты фармакогенетических исследований в наркологии. Показано, что система фармакогенетических маркеров может быть использована для построения полигенных предиктивных систем предварительного прогноза эффективности и переносимости в рамках персонализации фармакотерапии аддиктивной патологии. Кроме того, указывается, что методы генной инженерии могут являться новым перспективным подходом к патогенетической терапии болезней зависимости.

An overview of a number of research papers examines application of pharmacogenetic tests in narcology. It has been proven that a system of pharmacogenetic tests can be used for the development of a polygenic predictive system which can provide a preliminary forecast of effectiveness and tolerability of a treatment as part of the individualization of addiction pharmacotherapy. Moreover, methods of genetic engineering can be a new emerging approach in the treatment of addiction.

фармакогенетикафармакотерапияболезни зависимостиперсонализированная наркологияpharmacogeneticspharmacotherapyaddiction diseasespersonalized addiction psychiatryReferencesКибитов А.О., Бродянский В.М., Рыбакова К.В., Соловьва М.Г., Скурат Е.П., Чупрова Н.А., Николишин А.Е., Крупицкий Е.М. Фармакогенетические маркеры эффективности терапии алкогольной зависимости прегабалином — модулятором систем ГАМК и глутамата. Вопросы наркологии. 2018;10-11:101-150.Kibitov A.O., Brodyansky V.M., Rybakova K.V., Solovva M.G., Skurat E.P., Chuprova N.A., Nikolishin A.E., Krupitsky E.M. Pharmacogenetic markers of the effectiveness of alcohol dependence therapy with pregabalin, a modulator of GABA and glutamate systems. Voprosy narkologii. 2018;10-11:101-150. (In Russ.)Крупицкий Е. М. Применение фармакологических средств для стабилизации ремиссий и профилактики рецидивов при алкоголизме: зарубежные исследования. Вопросы наркологии. 2003;1:51-61.Krupitsky E.M. The use of pharmacological agents to stabilize remissions and prevent relapse in alcoholism: foreign studies. Voprosy narkologii. 2003;1:51-61. (In Russ.)Крупицкий Е.М. Краткосрочное интенсивное психотерапевтическое вмешательство в наркологии с позиций доказательной медицины. Неврологический вестник. 2010;42(3):2527.Krupitsky E.M. Short-term intensive psychotherapeutic intervention in narcology from the standpoint of evidence-based medicine. Nevrologicheskiy vestnik. 2010;42(3):25-27. (In Russ.)Крупицкий Е.М., Кибитов А.О., Блохина Е.А., Вербицкая Е.В., Бродянский В.М., Алексеева Н.П., Бушара Н.М., Ярославцева Т.С., Палаткин В.Я., Масалов Д.В., Бураков A.M., Романова Т.Н., Сулимов Г.Ю., Костен Т., Ниелсен Д., Звартау Э.Э., Вуди Д. Стабилизация ремиссий у больных опийной наркоманией имплантом налтрексона: фармакогенетический аспект. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015:115(4):14-23.Krupitsky E.M., Kibitov A.O., Blokhina E.A., Verbitskaya E.V., Brodyansky V.M., Alekseeva N.P., Bushara N.M., Yaroslavtseva T.S., Palatkin V.Ya., Masalov D.V., Burakov AM, Romanova T.N., Sulimov G.Yu., Kosten T., Nielsen D., Zvartau E.E., Woody D. Stabilization of remissions in patients with opium addiction Naltrexone implant: pharmacogenetic aspect. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015:115(4):14-23. (In Russ.).Крупицкий Е.М., Рыбакова К.В., Скурат Е.П., Михайлов А.Д, Незнанов Н.Г. Двойное слепое рандомизированное плацебо-контролируемое исследование эффективновности применения прегабалина для лечения синдрома зависимости от алкоголя. Вопросы наркологии. 2017;8:81-82.Krupitsky E.M., Rybakova K.V., Skurat E.P., Mikhailov A.D., Neznanov N.G. Double-blind, randomized, placebo-controlled study of the effectiveness of the use of pregabalin for the treatment of alcohol dependence syndrome. Voprosy narkologii. 2017;8:81-82. (In Russ.)Addolorato, Giovanni, Antonio Mirijello, and Lorenzo Leggio. «Alcohol addiction: toward a patientoriented pharmacological treatment.» (2013):p. 2157-2160. DOI: 10.1517/14656566.2013.834047Addolorato, Giovanni, Antonio Mirijello, and Lorenzo Leggio. «Alcohol addiction: toward a patientoriented pharmacological treatment.» (2013):p. 2157-2160. DOI: 10.1517/14656566.2013.834047Anton R.F., Oroszi G., O’Malley S., Couper D., Swift R., Pettinati H., Goldman D. An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of general psychiatry. 2008;65(2): 135-144. DOI:10.1001/ archpsyc.65.2.135Anton R.F., Oroszi G., O’Malley S., Couper D., Swift R., Pettinati H., Goldman D. An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of general psychiatry. 2008;65(2): 135-144. DOI:10.1001/ archpsyc.65.2.135Arias A. J., Armeli S., Gelernter J., Covault J., Kallio A., Karhuvaara S., Kranzler H. R. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcoholism: Clinical and Experimental Research. — 2008;32(7):11591166. DOI:10.1111/j.1530-0277.2008.00735.x.Arias A. J., Armeli S., Gelernter J., Covault J., Kallio A., Karhuvaara S., Kranzler H. R. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcoholism: Clinical and Experimental Research. — 2008;32(7):11591166. DOI:10.1111/j.1530-0277.2008.00735.x.Attilia F., Perciballi, R., Rotondo, C., Capriglione, I., Iannuzzi, S., Attilia, M. L., Ceccanti, M. Pharmacological treatment of alcohol use disorder. Scientific evidence. Rivista di psichiatria. 2018;53(3):123127. DOI:10.1708/2925.29414Attilia F., Perciballi, R., Rotondo, C., Capriglione, I., Iannuzzi, S., Attilia, M. L., Ceccanti, M. Pharmacological treatment of alcohol use disorder. Scientific evidence. Rivista di psichiatria. 2018;53(3):123127. DOI:10.1708/2925.29414Bhaduri N., Mukhopadhyay K. Correlation of plasma dopamine β-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population. Cellular and molecular neurobiology. 2008;28(3):343350. DOI:10.1007/s10571-007-9256-8Bhaduri N., Mukhopadhyay K. Correlation of plasma dopamine β-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population. Cellular and molecular neurobiology. 2008;28(3):343350. DOI:10.1007/s10571-007-9256-8Clarke T. K., Crist R. C., Ang A., Ambrose-Lanci L. M., Lohoff F. W., Saxon A. J., Berrettini W. H. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. The pharmacogenomics journal. 2014;14(3):303. DOI: 10.1038/ tpj.2013.30Clarke T. K., Crist R. C., Ang A., Ambrose-Lanci L. M., Lohoff F. W., Saxon A. J., Berrettini W. H. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. The pharmacogenomics journal. 2014;14(3):303. DOI: 10.1038/ tpj.2013.30Correa Filho JM, Baltieri DA. A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil. Addictive Behaviors. 2013;38(4):2044–2051. DOI:10.1016/j.addbeh.2012.12.018Correa Filho JM, Baltieri DA. A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil. Addictive Behaviors. 2013;38(4):2044–2051. DOI:10.1016/j.addbeh.2012.12.018Crist R. C., Phillips K. A., Furnari M. A., Moran L. M., Doyle G. A., McNicholas L. F., Berrettini W. H. Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African– Americans with opioid use disorder. The pharmacogenomics journal. 2019;19(3):260. DOI: 10.1038/ s41397-018-0065-xCrist R. C., Phillips K. A., Furnari M. A., Moran L. M., Doyle G. A., McNicholas L. F., Berrettini W. H. Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African– Americans with opioid use disorder. The pharmacogenomics journal. 2019;19(3):260. DOI: 10.1038/ s41397-018-0065-xDel Re AC, Maisel N, Blodgett J, Finney J. The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: A multivariate meta-analysis. Alcoholism: Clinical and Experimental Research. 2013;37(6):1064–1068. doi: 10.1111/ acer.12067Del Re AC, Maisel N, Blodgett J, Finney J. The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: A multivariate meta-analysis. Alcoholism: Clinical and Experimental Research. 2013;37(6):1064–1068. doi: 10.1111/ acer.12067Deinum J., Steenbergen-Spanjers G. C. H., Jansen M., Boomsma F., Lenders J. W. M., van Ittersum F. J., Wevers, R. A. DBH gene variants that cause low plasma dopamine β hydroxylase with or without a severe orthostatic syndrome. Journal of medical genetics. 2004;41(4): e38-e38. DOI:10.1136/ jmg.2003.009282Deinum J., Steenbergen-Spanjers G. C. H., Jansen M., Boomsma F., Lenders J. W. M., van Ittersum F. J., Wevers, R. A. DBH gene variants that cause low plasma dopamine β hydroxylase with or without a severe orthostatic syndrome. Journal of medical genetics. 2004;41(4): e38-e38. DOI:10.1136/ jmg.2003.009282Gaval-Cruz M., Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Molecular Interventions. 2009;9(4):175. DOI: 10.1124/mi.9.4.6Gaval-Cruz M., Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Molecular Interventions. 2009;9(4):175. DOI: 10.1124/mi.9.4.6Harris J. F., Micheva-Viteva S., Li, N., Hong-Geller E. (2013). Small RNA-mediated regulation of host– pathogen interactions. Virulence. (2013);4(8):785795. DOI.org/10.4161/viru.26119Harris J. F., Micheva-Viteva S., Li, N., Hong-Geller E. (2013). Small RNA-mediated regulation of host– pathogen interactions. Virulence. (2013);4(8):785795. DOI.org/10.4161/viru.26119Johnstone E.C., Yudkin P.L., Hey K., Roberts S.J., Welch S.J., Murphy M.F., Griffiths S.E., Walton R.T. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics and Genomics. 2004;14(2):8390. DOI:10.1097/00008571-200402000-00002Johnstone E.C., Yudkin P.L., Hey K., Roberts S.J., Welch S.J., Murphy M.F., Griffiths S.E., Walton R.T. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics and Genomics. 2004;14(2):8390. DOI:10.1097/00008571-200402000-00002Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000;284(8):963–971. doi:10.1001/jama.284.8.963Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000;284(8):963–971. doi:10.1001/jama.284.8.963Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet. 2003;361(9370):1677–1685. DOI:10.1016/ s0140-6736(03)13370-3Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet. 2003;361(9370):1677–1685. DOI:10.1016/ s0140-6736(03)13370-3Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA. 2007;298(14):1641– 1651. DOI:10.1001/jama.298.14.1641Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA. 2007;298(14):1641– 1651. DOI:10.1001/jama.298.14.1641Johnson B. A., Ait-Daoud N., Seneviratne C., Roache J. D., Javors M. A., Wang X. Q., Li M. D. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. American Journal of Psychiatry. 2011;168(3):265-275. DOI:10.1176/appi. ajp.2010.10050755Johnson B. A., Ait-Daoud N., Seneviratne C., Roache J. D., Javors M. A., Wang X. Q., Li M. D. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. American Journal of Psychiatry. 2011;168(3):265-275. DOI:10.1176/appi. ajp.2010.10050755Johnson BA, Seneviratne C, Wang XQ, et al. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. American Journal of Psychiatry. 2013;170(9):1020–1031. DOI: 10.1176/appi.ajp.2013.12091163Johnson BA, Seneviratne C, Wang XQ, et al. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. American Journal of Psychiatry. 2013;170(9):1020–1031. DOI: 10.1176/appi.ajp.2013.12091163Israel Y. Quintanilla, M. E., Karahanian, E., Rivera‐Meza, M., & Herrera‐Marschitz, M.The “first hit” toward alcohol reinforcement: role of ethanol metabolites. Alcoholism: Clinical and Experimental Research. 2015;39(5):776-786. DOI: 10.1111/ acer.12709Israel Y. Quintanilla, M. E., Karahanian, E., Rivera‐Meza, M., & Herrera‐Marschitz, M.The “first hit” toward alcohol reinforcement: role of ethanol metabolites. Alcoholism: Clinical and Experimental Research. 2015;39(5):776-786. DOI: 10.1111/ acer.12709Karahanian E., Quintanilla M.E., Tampier L., Rivera-Meza M., Bustamante D., Gonzalez-Lira V., Morales P., Herrera-Marschitz M., Israel Y. Ethanol as a prodrug: brain metabolism of ethanol mediates its reinforcing effects. Alcoholism: Clinical and Experimental Research. 2011;35(4):606612. DOI: 10.1111/j.1530-0277.2011.01439.xKarahanian E., Quintanilla M.E., Tampier L., Rivera-Meza M., Bustamante D., Gonzalez-Lira V., Morales P., Herrera-Marschitz M., Israel Y. Ethanol as a prodrug: brain metabolism of ethanol mediates its reinforcing effects. Alcoholism: Clinical and Experimental Research. 2011;35(4):606612. DOI: 10.1111/j.1530-0277.2011.01439.xKarahanian E., Rivera-Meza M., Tampier L., Quintanilla M.E., Herrera-Marschitz M., Israel Y. Longterm inhibition of ethanol intake by the administration of an aldehyde dehydrogenase‐2 (ALDH 2)‐coding lentiviral vector into the ventral tegmental area of rats. Addiction Biology. 2015;20(2):336344. DOI:10.1111/adb.12130Karahanian E., Rivera-Meza M., Tampier L., Quintanilla M.E., Herrera-Marschitz M., Israel Y. Longterm inhibition of ethanol intake by the administration of an aldehyde dehydrogenase‐2 (ALDH 2)‐coding lentiviral vector into the ventral tegmental area of rats. Addiction Biology. 2015;20(2):336344. DOI:10.1111/adb.12130Karpyak V. M., Biernacka J. M., Geske J. R., Jenkins G. D., Cunningham, J. M., Rüegg J., Loukianova L. L. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Translational psychiatry. 2014;4(10):1-7. DOI:10.1038/tp.2014.103Karpyak V. M., Biernacka J. M., Geske J. R., Jenkins G. D., Cunningham, J. M., Rüegg J., Loukianova L. L. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Translational psychiatry. 2014;4(10):1-7. DOI:10.1038/tp.2014.103Kiefer F., Witt S. H., Frank J., Richter A., Treutlein J., Lemenager T., Wodarz N. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. The pharmacogenomics journal. 2011;11(5):368. DOI:10.1038/ tpj201051Kiefer F., Witt S. H., Frank J., Richter A., Treutlein J., Lemenager T., Wodarz N. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. The pharmacogenomics journal. 2011;11(5):368. DOI:10.1038/ tpj201051King D. P., Paciga S., Pickering E., Benowitz N. L., Bierut L. J., Conti D. V., Park P. W. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012; 37(3):641. DOI:10.1038/npp.2011.232King D. P., Paciga S., Pickering E., Benowitz N. L., Bierut L. J., Conti D. V., Park P. W. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012; 37(3):641. DOI:10.1038/npp.2011.232Köhnke M. D., Zabetian C. P., Anderson G. M., Kolb W., Gaertner I., Buchkremer G., Cubells J. F. A genotype-controlled analysis of plasma dopamine β-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biological psychiatry. 2002;52(12):1151-1158. DOI:10.1016/S00063223(02)01427-0Köhnke M. D., Zabetian C. P., Anderson G. M., Kolb W., Gaertner I., Buchkremer G., Cubells J. F. A genotype-controlled analysis of plasma dopamine β-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biological psychiatry. 2002;52(12):1151-1158. DOI:10.1016/S00063223(02)01427-0Kranzler H. R. Armeli, S., Tennen, H., Covault, J., Feinn, R., Arias, A. J., Oncken, C. A doubleblind, randomized trial of sertraline for alcohol dependence: moderation by age of onset and 5-HTTLPR genotype. Journal of clinical psychopharmacology. 2011;31(1):22. DOI:10.1097/ JCP.0b013e31820465fa.Kranzler H. R. Armeli, S., Tennen, H., Covault, J., Feinn, R., Arias, A. J., Oncken, C. A doubleblind, randomized trial of sertraline for alcohol dependence: moderation by age of onset and 5-HTTLPR genotype. Journal of clinical psychopharmacology. 2011;31(1):22. DOI:10.1097/ JCP.0b013e31820465fa.Kranzler H. R., Covault J., Feinn R., Armeli S., Tennen H., Arias A. J., Kampman K. M. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. American Journal of Psychiatry. 2014;171(4):445-452. DOI: 10.1037/a0037309Kranzler H. R., Covault J., Feinn R., Armeli S., Tennen H., Arias A. J., Kampman K. M. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. American Journal of Psychiatry. 2014;171(4):445-452. DOI: 10.1037/a0037309Krupitsky E., Rybakova K., Skurat E., Mikhailov A., Neznanov N. Pregabalin reduces smoking and drinking in alcohol dependent subjects. European Neuropsychopharmacology. 2019;29(1):S176-S177. DOI: 10.1016/j.euroneuro.2018.11.300Krupitsky E., Rybakova K., Skurat E., Mikhailov A., Neznanov N. Pregabalin reduces smoking and drinking in alcohol dependent subjects. European Neuropsychopharmacology. 2019;29(1):S176-S177. DOI: 10.1016/j.euroneuro.2018.11.300Latt N., Conigrave K., Saunders J., Marshall E.J., Nutt D. Addiction Medicine. Oxford University Press, 2009,459p.Latt N., Conigrave K., Saunders J., Marshall E.J., Nutt D. Addiction Medicine. Oxford University Press, 2009,459p.Morley K. C. Luquin N., Baillie A., Fraser I., Trent R. J., Dore G., Haber P. S. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction. 2018;113(12):2205-2213. DOI:10.1111/ add.14373Morley K. C. Luquin N., Baillie A., Fraser I., Trent R. J., Dore G., Haber P. S. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction. 2018;113(12):2205-2213. DOI:10.1111/ add.14373Munafo M.R., Elliot K.M., Murphy M.F., Walton R.T., Johnstone E.C. Association of the muopioid receptor gene with smoking cessation. The pharmacogenomics journal. 2007;7(5):353–361. DOI:10.1038/6500432Munafo M.R., Elliot K.M., Murphy M.F., Walton R.T., Johnstone E.C. Association of the muopioid receptor gene with smoking cessation. The pharmacogenomics journal. 2007;7(5):353–361. DOI:10.1038/6500432Mutschler J., Abbruzzese E., Witt S. H., Dirican G., Nieratschker V., Frank J., Kiefer F. Functional polymorphism of the dopamine β-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. Journal of clinical psychopharmacology. 2012;32(4):578580. DOI:10.1097/JCP.0b013e31825ddbe6Mutschler J., Abbruzzese E., Witt S. H., Dirican G., Nieratschker V., Frank J., Kiefer F. Functional polymorphism of the dopamine β-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. Journal of clinical psychopharmacology. 2012;32(4):578580. DOI:10.1097/JCP.0b013e31825ddbe6Ooteman W., Michael N., Koeter M., Verheul R., Schippers G., Houchi H., Van den Brink W. Predicting the Effect of Naltrexone and Acamprosate in Alcohol-dependent Patients Using Phenotypic, Endophenotypic and Genetic Indicators. Behavior Genetics. 2007;37(6):781-782. DOI:10.1111/j.13691600.2009.00159.xOoteman W., Michael N., Koeter M., Verheul R., Schippers G., Houchi H., Van den Brink W. Predicting the Effect of Naltrexone and Acamprosate in Alcohol-dependent Patients Using Phenotypic, Endophenotypic and Genetic Indicators. Behavior Genetics. 2007;37(6):781-782. DOI:10.1111/j.13691600.2009.00159.xOslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., O’Brien C.P. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcoholdependent patients. Neuropsychopharmacology. 2003;28(8):1546–1552. DOI:10.1038/1300219Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., O’Brien C.P. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcoholdependent patients. Neuropsychopharmacology. 2003;28(8):1546–1552. DOI:10.1038/1300219Oslin D. W., Leong S. H., Lynch K. G., Berrettini W., O’Brien C. P., Gordon A. J., Rukstalis M. Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA psychiatry. 2015;72(5):430-437. DOI:10.1001/jamapsychiatry.2014.3053Oslin D. W., Leong S. H., Lynch K. G., Berrettini W., O’Brien C. P., Gordon A. J., Rukstalis M. Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA psychiatry. 2015;72(5):430-437. DOI:10.1001/jamapsychiatry.2014.3053Ray L. A., Miranda Jr, R., MacKillop J., McGeary J., Tidey J. W., Rohsenow D. J., Monti P. M. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Experimental and clinical psychopharmacology. 2009;17 (2):122. DOI:10.1037/a0015700.Ray L. A., Miranda Jr, R., MacKillop J., McGeary J., Tidey J. W., Rohsenow D. J., Monti P. M. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Experimental and clinical psychopharmacology. 2009;17 (2):122. DOI:10.1037/a0015700.Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: Implications for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology. 2009;29(6):584–589. DOI:10.1097/JCP.0b013e3181bfdb79Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: Implications for the treatment of alcohol dependence. Journal of Clinical Psychopharmacology. 2009;29(6):584–589. DOI:10.1097/JCP.0b013e3181bfdb79Salloum N. C., Buchalter E. L., Chanani S., Espejo G., Ismail M. S., Laine R. O., Vance E. From genesto treatments: a systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics. 2018;19(10):861-871. DOI:10.2217/pgs-2018-0023Salloum N. C., Buchalter E. L., Chanani S., Espejo G., Ismail M. S., Laine R. O., Vance E. From genesto treatments: a systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics. 2018;19(10):861-871. DOI:10.2217/pgs-2018-0023Seneviratne C., Johnson B. A. Advances in medications and tailoring treatment for alcohol use disorder. Alcohol research: current reviews. 2015;37(1):15. DOI:10.0000/www.ncbi.nlm.nih.gov/PMC44Seneviratne C., Johnson B. A. Advances in medications and tailoring treatment for alcohol use disorder. Alcohol research: current reviews. 2015;37(1):15. DOI:10.0000/www.ncbi.nlm.nih.gov/PMC44Sturgess J. E., George T. P., Kennedy J. L., Heinz A., Müller D. J. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addiction biology. 2011;16(3):357-376. DOI:10.1111/j.13691600.2010.00287.xSturgess J. E., George T. P., Kennedy J. L., Heinz A., Müller D. J. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addiction biology. 2011;16(3):357-376. DOI:10.1111/j.13691600.2010.00287.xThanos P. K., Volkow N. D., Freimuth P., Umegaki H., Ikari H., Roth G., Hitzemann R. Overexpression of dopamine D2 receptors reduces alcohol self‐administration. Journal of neurochemistry. 2001;78(5):1094-1103. DOI:10.1046/j.14714159.2001.00492.xThanos P. K., Volkow N. D., Freimuth P., Umegaki H., Ikari H., Roth G., Hitzemann R. Overexpression of dopamine D2 receptors reduces alcohol self‐administration. Journal of neurochemistry. 2001;78(5):1094-1103. DOI:10.1046/j.14714159.2001.00492.xVolkow N.D., Wang G.J., Fowler J. S., Tomasi D., Telang F., Baler R. Addiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain’s control circuit. Bioessays. 2010;32(9):748-755. DOI: 10.1002/ bies.201000042Volkow N.D., Wang G.J., Fowler J. S., Tomasi D., Telang F., Baler R. Addiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain’s control circuit. Bioessays. 2010;32(9):748-755. DOI: 10.1002/ bies.201000042Zabetian C.P., Anderson G. M., Buxbaum S.G., Elston R. C., Ichinose H., Nagatsu T., Cubells J. F. A quantitative-trait analysis of human plasma– dopamine β-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. The American Journal of Human Genetics. 2001;68(2):515-522. DOI:10.1086/318198Zabetian C.P., Anderson G. M., Buxbaum S.G., Elston R. C., Ichinose H., Nagatsu T., Cubells J. F. A quantitative-trait analysis of human plasma– dopamine β-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. The American Journal of Human Genetics. 2001;68(2):515-522. DOI:10.1086/318198

The authors declare that there are no conflicts of interest present.